is tirzepatide still on the fda shortage list resolves shortage, impacting compounding pharmacies Mounjaro will remain off shortage

Visible results: Gradual fat reduction over a few weeks

Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through -5 studies (abstract)

The metanalysis includes 5,323 patients (56-61 years) with T2D inadequately controlled (HbA 1c 7-10.5%), baseline BMI 23-45 kg/m 2 , mean diabetes duration of 9-12 years, and randomized to receive a GLP-1RA or GIP/GLP-1RA versus placebo in add on to basal insulin for at least 24 weeks (24-40 weeks)

Danuglipron: Developed by Pfizer and intended to keep blood glucose at healthy levels, this oral GLP-1 recently completed Phase 2 clinical trials for the treatment of type 2 diabetes and obesity

GLP-1s arent a shortcut

The recently published CAROLINA study, which compared the cardiovascular-safe DPP-4 inhibitor linagliptin [61] with the sulfonylurea glimepiride, showed that glimepiride does not increase the risk of hospitalization for heart failure [62]